Regentis Biomaterials CEO Highlights GelrinC's European Approval and U.S. Pivotal Trial on BioMedWire Podcast

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing its regenerative medicine platform with its lead product GelrinC(R), a cell-free, off-the-shelf hydrogel implant designed to treat cartilage injuries in the knee. In a recent episode of The BioMedWire Podcast, Executive Chairman and CEO Dr. Ehud Geller provided an update on the company's clinical and commercial progress, underscoring the potential of GelrinC to address a significant unmet need in orthopedic medicine.

Geller noted that GelrinC is already approved for marketing in Europe and is currently undergoing a U.S. pivotal clinical trial. Regentis is working to expand clinical sites and aims to complete enrollment around year-end. This milestone is critical because successful completion of the trial could pave the way for U.S. regulatory approval, opening access to a market estimated at 470,000 currently untreated cases annually. According to the company, no off-the-shelf treatment is currently available for these patients, representing a substantial opportunity for Regentis if GelrinC gains approval.

The technology behind GelrinC is based on Regentis' Gelrin platform, which uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC is designed to be eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This approach could offer a less invasive, off-the-shelf solution compared to existing treatments, which often require two surgeries or long recovery periods.

In addition to U.S. clinical progress, Regentis is actively pursuing European commercialization. Geller mentioned discussions with distribution systems and major orthopedic companies to advance market penetration. Europe represents an immediate revenue opportunity since GelrinC is already approved there, and partnerships with established distributors could accelerate adoption. The company's dual focus on U.S. trials and European commercialization reflects a strategic effort to build a global presence in the regenerative orthopedic market.

The implications of Regentis' progress extend beyond the company itself. If GelrinC succeeds in the U.S. pivotal trial, it could become the first off-the-shelf treatment for cartilage knee repair, potentially transforming the standard of care. This could reduce the need for more invasive procedures and provide a more accessible option for the 470,000 patients annually who currently go untreated. For investors, the completion of enrollment and subsequent trial results will be key catalysts to watch.

For more details, the full press release is available at https://ibn.fm/4Tu64. Additionally, the latest news and updates relating to RGNT can be found in the company's newsroom at https://ibn.fm/RGNT. BioMedWire, the platform that hosted the podcast, provides specialized communications focused on biotechnology, biomedical sciences, and life sciences. More information about BioMedWire is available at https://www.BioMedWire.com.